Skip to main content
. 2012 Aug;136(4):437–447. doi: 10.1111/j.1365-2567.2012.03600.x

Figure 5.

Figure 5

(a) C57BL/6 mice were challenged with MCA205 and treated at day 10 with 250 μg αOX40 or control RatIg. Half of these mice received additional treatment with daily intraperitoneal injections of the arginase inhibitor NOHA (10 mg/kg) from day 12. Tumours were harvested at day 17 for analysis of tumour-infiltrating cells. Graphs show the mean and standard deviation of tumour-infiltrating CD8 T cells and CD11b+ Gr1hi IAlow macrophages. (b) Survival of C57BL/6 mice challenged with MCA205 and treated at day 10 and day 17 with 250 μg αOX40 or control RatIg. Half of these mice received additional treatment with daily intraperitoneal injections of the arginase inhibitor NOHA (10 mg/kg) from day 12 to day 19. NS: not significant; *P < 0·05; **P < 0·01; ***P < 0·001.